ALLO - Allogene Therapeutics, Inc.

2.26
-0.150   -6.637%

Share volume: 6,274,221
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$2.41
-0.15
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.38%
1 Month
-14.72%
3 Months
63.77%
6 Months
77.95%
1 Year
45.81%
2 Year
-49.44%
Key data
Stock price
$2.26
P/E Ratio 
N/A
DAY RANGE
$2.26 - $2.50
EPS 
-$0.87
52 WEEK RANGE
$0.86 - $2.80
52 WEEK CHANGE
$54.79
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
243.778 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,711,930
AVERAGE 30 VOLUME 
$5,800,315
Company detail
CEO: David D. Chang
Region: US
Website: allogene.com
Employees: 310
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Recent news